Nivolumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Diseases
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Trial Timeline
Jun 27, 2019 → Mar 18, 2021
NCT ID
NCT03656627About Nivolumab
Nivolumab is a phase 1 stage product being developed by Bristol Myers Squibb for Autoimmune Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT03656627. Target conditions include Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03126643 | Pre-clinical | Completed |
| NCT02475382 | Pre-clinical | Completed |
| NCT06523621 | Phase 2 | Recruiting |
| NCT06499298 | Pre-clinical | Completed |
| NCT06735781 | Pre-clinical | Completed |
| NCT06421311 | Pre-clinical | Terminated |
| NCT06452329 | Pre-clinical | Completed |
| NCT06003075 | Phase 2 | Terminated |
| NCT06361576 | Pre-clinical | Completed |
| NCT06361563 | Pre-clinical | Completed |
| NCT05068609 | Pre-clinical | Completed |
| NCT04936399 | Pre-clinical | Completed |
| NCT04205409 | Phase 2 | Active |
| NCT04401774 | Phase 2 | Completed |
| NCT04361058 | Phase 1 | Withdrawn |
| NCT04022980 | Phase 1 | Completed |
| NCT04019964 | Phase 2 | Completed |
| NCT04146324 | Pre-clinical | Completed |
| NCT04099251 | Phase 3 | Active |
| NCT03981146 | Phase 2 | Active |
Competing Products
20 competing products in Autoimmune Diseases